Publications 2022

Leiva RA, Bergersen BM, Finbråten AK, Sandvei PK, Simonsen Ø, Rosseland CM, Hagen K, Young L, Roberts RS, Mikkelsen Y, Singh R, Lagging M, Dalgard O (2022)
High real-world effectiveness of 12-week elbasvir/grazoprevir without resistance testing in the treatment of patients with HCV genotype 1a infection in Norway
Scand J Gastroenterol, 58 (3), 264-268
DOI 10.1080/00365521.2022.2118555, PubMed 36063075

Publications 2020

Whittaker R, Nilsen O, Myrberg AJ, Angeltvedt RM, Bergersen BM, Klovstad H (2020)
Norway is in the process of stopping the HIV epidemic
Tidsskr. Nor. Laegeforen., 140 (18), 1864-1866

Whittaker R, Nilsen Ø, Myrberg AJ, Angeltvedt RM, Bergersen BM, Kløvstad H (2020)
Norway is on the verge of ending the HIV epidemic
Tidsskr Nor Laegeforen, 140 (18)
DOI 10.4045/tidsskr.20.0748, PubMed 33322887

Publications 2011

Brandsaeter BJ, Pillgram M, Berild D, Kjekshus H, Kran AM, Bergersen BM (2011)
Hospitalised patients with suspected 2009 H1N1 influenza A in a hospital in Norway, July - December 2009
BMC Infect Dis, 11, 75
DOI 10.1186/1471-2334-11-75, PubMed 21435254

Publications 2009

Skeie L, Bugge H, Negaard A, Bergersen BM (2009)
Large particle hyaluronic acid for the treatment of facial lipoatrophy in HIV-positive patients: 3-year follow-up study
HIV Med, 11 (3), 170-7
DOI 10.1111/j.1468-1293.2009.00761.x, PubMed 19780861

Publications 2006

Bergersen BM (2006)
Cardiovascular risk in patients with HIV Infection: impact of antiretroviral therapy
Drugs, 66 (15), 1971-87
DOI 10.2165/00003495-200666150-00006, PubMed 17100407

Bergersen BM, Schumacher A, Sandvik L, Bruun JN, Birkeland K (2006)
Important differences in components of the metabolic syndrome between HIV-patients with and without highly active antiretroviral therapy and healthy controls
Scand J Infect Dis, 38 (8), 682-9
DOI 10.1080/00365540500361302, PubMed 16857615

Publications 2005

Bergersen BM (2005)
The lipodystrophy syndrome in HIV-positive patients: body composition changes and cardiovascular risk factors
Department of Infectious Diseases, Ullevål University Hospital Faculty of Medicine, University of Oslo, Oslo, 1 b. (flere pag.)
BIBSYS 051513463, ISBN 82-8080-144-8

Bergersen BM, Sandvik L, Ellingsen I, Bruun JN (2005)
Lipoatrophic men 44 months after the diagnosis of lipoatrophy are less lipoatrophic but more hypertensive
HIV Med, 6 (4), 260-7
DOI 10.1111/j.1468-1293.2005.00305.x, PubMed 16011531

Bergersen BM, Tonstad S, Sandvik L, Bruun JN (2005)
Low prevalence of high-density lipoprotein cholesterol level < 1 mmol/L in non-nucleoside reverse transcriptase inhibitor recipients
Int J STD AIDS, 16 (5), 365-9
DOI 10.1258/0956462053888808, PubMed 15949067

Publications 2004

Bergersen BM, Sandvik L, Bruun JN (2004)
Body composition changes in 308 Norwegian HIV-positive patients
Scand J Infect Dis, 36 (3), 186-91
DOI 10.1080/00365540410019273, PubMed 15119363

Bergersen BM, Sandvik L, Bruun JN, Tonstad S (2004)
Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects
Eur J Clin Microbiol Infect Dis, 23 (8), 625-30
DOI 10.1007/s10096-004-1177-6, PubMed 15322938

Publications 2003

Bergersen BM, Sandvik L, Dunlop O, Birkeland K, Bruun JN (2003)
Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-naïve and HIV-negative controls: results from a Norwegian study of 721 patients
Eur J Clin Microbiol Infect Dis, 22 (12), 731-6
DOI 10.1007/s10096-003-1034-z, PubMed 14610658

Sandvik L, Dunlop O, Birkeland KI, Bruun JN, Bergersen BM (2003)
Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-naive and HIV-negative controls: results from a Norwegian study of 721 patients
In European journal of clinical microbiology & infectious diseases, Vieweg, Wiesbaden, 22(2003)12, s.731-6
BIBSYS 041705173